First-Quarter Figures: Sartorius Stedim Biotech off to a Dynamic Start into 2016

Regulatory News:

Sartorius Stedim Biotech (Paris:DIM):

    
      
        
          € in millions
        
        
           
        
        
          3 months
        
        
           
        
        
          3 months
        
        
           
        
        
          Growth in %
        
        
           
        
        
          Growth
        
        
        
      
      
        
          unless otherwise
        
        
        
        
          2016
        
        
        
        
          2015
        
        
        
        
        
        
        
        
          in %
        
        
        
      
      
        
          specified Unaudited
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
          const. fx
        
        
        
      
      
        
          figures
        
        
           
        
        
           
        
        
           
        
        
           
        
        
           
        
        
           
        
        
           
        
        
           
        
        
        
      
      
        
          Order intake
        
        
           
        
        
          274.1
        
        
           
        
        
          224.1
        
        
           
        
        
          22.3
        
        
           
        
        
          23.0
        
        
        
      
      
        
          Sales revenue
        
        
           
        
        
          245.8
        
        
           
        
        
          204.4
        
        
           
        
        
          20.2
        
        
           
        
        
          20.9
        
        
        
      
      
        
          EMEA1
        
        
           
        
        
          114.1
        
        
           
        
        
          97.3
        
        
           
        
        
          17.2
        
        
           
        
        
          18.0
        
        
        
      
      
        
          Americas1
        
        
           
        
        
          91.0
        
        
           
        
        
          70.2
        
        
           
        
        
          29.7
        
        
           
        
        
          29.3
        
        
        
      
      
        
          Asia | Pacific1
        
        
           
        
        
          40.7
        
        
           
        
        
          36.9
        
        
           
        
        
          10.1
        
        
           
        
        
          12.8
        
        
        
      
      
        
          EBITDA2
        
        
           
        
        
          64.6
        
        
           
        
        
          50.8
        
        
           
        
        
          27.2
        
        
           
        
        
           
        
        
        
      
      
        
          EBITDA margin2 in %
        
        
           
        
        
          26.3
        
        
           
        
        
          24.8
        
        
           
        
        
           
        
        
           
        
        
           
        
        
        
      
      
        
          Net profit3
        
        
           
        
        
          39.4
        
        
           
        
        
          29.6
        
        
           
        
        
          33.0
        
        
           
        
        
           
        
        
        
      
      
        
          Earnings per share3 in €
        
        
           
        
        
          2.57
        
        
           
        
        
          1.93
        
        
           
        
        
          32.9
        
        
           
        
        
           
        
        
        
      
    
    

1 According to customers’ location

2 Underlying EBITDA = earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items

3 Underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items, non-cash amortization and based on a normalized financial result and tax rate

Strong double-digit topline growth

Within a continued dynamic market environment, Sartorius Stedim Biotech (SSB), a leading supplier for the biopharma industry, reported a strong first quarter 2016, with sales revenue up 20.9%. Besides strong operating performance, this high growth rate was positively impacted by first-time consolidation of the recent acquisitions of BioOutsource (April 2015) and Cellca (July 2015), which contributed a good 3 percentage points to growth, and also by the relatively easy comparables from the prior-year quarter. Expansion was driven by high demand across the entire portfolio, especially for single-use products. Regionally, the Americas led growth, posting a gain of nearly 30%, while EMEA and Asia also grew by double digits.

Profits on the rise

Mainly driven by economies of scale, SSB’s earnings increased overproportionately. Underlying EBITDA soared 27.2% to 64.6 million euros; the corresponding margin reached 26.3%. Underlying earnings per share were 2.57 euros, up year over year from 1.93 euros.

Strong financial position

The financial position of SSB strengthened even further as reflected by an equity ratio of 60.9% and a ratio of net debt to underlying EBITDA of 0.3. Net debt at the end of the first quarter was 76.3 million euros.

Positive outlook for 2016

Based on the strong results of the first three months, management confirms its forecast for the full year of 2016. Sales revenue is expected to increase by about 12% to 16% in constant currencies. The underlying EBITDA margin is projected to rise approx. one percentage point in constant currencies compared with the prior-year figure of 26.2%.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference call

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the company’s results with analysts and investors on Wednesday, April 20, 2016, at 4:00 p.m. Central European Time (CET), in a teleconference. You may dial into the teleconference starting at 3:50 p.m. CET at the following numbers:

Germany: [phone]France: [phone]UK: [phone]USA: [phone]

The dial-in code is: 4277136To view the presentation, log onto: www.sartorius-stedim.com

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and in 2015 earned sales revenue of 884.3 million euros.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160419006919/en/

Sartorius Stedim BiotechPetra Kirchhoff, +49(0)551.308.1686Vice President of Corporate [e-mail]